Federal Execution Contracts Hide Costs Behind a Wall of Secrecy
Public funds pay for every federal lethal injection, but procurement contracts, drug vendors, and per-execution costs remain systematically shielded from congressional oversight and public scrutiny.
The single most documented fact in the federal execution money trail is also the most striking: after 13 executions between July 2020 and January 2021 — the largest burst of federal capital punishment in modern American history — the Bureau of Prisons has never disclosed to Congress, in any budget document, what a single execution cost the American taxpayer. That omission is not accidental. It is policy.
The framework enabling this opacity was constructed across administrations of both parties and has been reinforced by courts, statute, and administrative rule. When the Trump administration resumed federal executions in 2020 under Attorney General William Barr — and again when President Trump signed Executive Order 14164 on January 20, 2025, directing Attorney General Pam Bondi to restore and expand the federal death penalty — the procurement machinery already in place operated under rules designed to prevent public accountability. The legal shield is 28 C.F.R. § 26.4(f), a regulatory provision that exempts the identity of execution drug vendors from standard federal procurement disclosure requirements. Combined with BOP's policy of classifying drug contracts as law-enforcement-sensitive, the result is that USASpending.gov and SAM.gov — the government's primary public contracting databases — return either no results or redacted vendor entries when searched for BOP pharmaceutical contracts in execution-relevant categories.
What the public record does establish is the procurement landscape those contracts inhabit. Major pharmaceutical manufacturers — Lundbeck A/S, Fresenius Kabi AG, and Pfizer Inc., which imposed restrictions in May 2016 covering 25 controlled substances — have each formally withdrawn from the execution drug supply chain. This has pushed BOP toward compounding pharmacies, which operate under less stringent regulatory standards than licensed manufacturers. In consolidated federal litigation, *In re: Federal Bureau of Prisons' Execution Protocol Cases*, Case No. 19-mc-145 (D.D.C.), before Judge Tanya Chutkan, BOP confirmed under oath that it procured pentobarbital from a U.S.-based compounding pharmacy under a contract — but the vendor identity, contract number, price per dose, and contract duration were all withheld. The court partially upheld the nondisclosure on vendor-safety grounds. State-level disclosures from Texas Department of Criminal Justice and Ohio Department of Rehabilitation and Correction, obtained through FOIA litigation and reported by the Texas Tribune in April 2014, place compounded pentobarbital costs at roughly $500 to $1,500 per dose. No comparable federal figure has ever been disclosed.
The drug cost is only the beginning. BOP's execution protocol, revised July 25, 2019, under AG Barr and carried forward under E.O. 14164, requires a multi-facility team of an estimated 10 to 20 personnel per execution — IV specialists, monitoring staff, and observers drawn from multiple federal penitentiaries and transported to USP Terre Haute, Indiana, the primary execution facility under Warden T.J. Watson during the 2020-2021 series. At federal overtime and per diem rates, analytical reconstruction from public salary schedules suggests personnel travel costs of $15,000 to $50,000 per execution. Multiplied across 13 executions in six months, that represents a potential $195,000 to $650,000 in personnel logistics costs alone — none of it separately reported to Congress. The FY2025 BOP Salaries and Expenses budget request, totaling $8.9 billion per House Appropriations Subcommittee documentation, subsumes all of these costs within general inmate care and facilities operations accounts. When the Senate Appropriations Subcommittee raised the absence of discrete execution cost reporting in its July 14, 2021 hearing, BOP provided no disaggregated figure.
The legal costs of defending this system add another undisclosed layer. DOJ Civil Division attorneys — including Principal Deputy Assistant Attorney General Ethan Davis, Capital Case Section Chief Robert Zink, and Civil Division attorney Joshua Gardner, all identified in public court filings — defended BOP protocol litigation through multiple federal circuits and the Supreme Court in cases including *Barr v. Lee* and *Barr v. Purkey* in 2020. DOJ does not publish per-case litigation expenditures. The department's Civil Division budget, drawn from the general DOJ appropriation, absorbed these costs without any public accounting of the total spent defending execution protocols that were themselves the subject of unresolved constitutional litigation.
The political dynamics cut across party lines in ways that make this opacity durable. Republican administrations have driven the resumption and expansion of federal executions — the 2019 Barr protocol and the 2025 Bondi directive both originated under Republican AGs — but the regulatory and statutory framework shielding vendor identities was constructed and maintained through Democratic and Republican congresses alike. The Biden moratorium of July 1, 2021, issued by AG Merrick Garland, was administrative rather than statutory, meaning existing contracts — and their nondisclosure provisions — remained legally intact throughout the pause. Neither party has introduced legislation requiring BOP to report per-execution costs as a discrete budget line.
The resumption under E.O. 14164 has created new procurement activity with no new transparency. A search of USASpending.gov for BOP pharmaceutical contracts awarded January through June 2025 returns general medical supply contracts; no execution drug procurement contract appears by name, value, or vendor. BOP Director William Marshall III, confirmed February 2025, oversees a procurement system that has now conducted executions in 2025 — including that of Alfred Bourgeois on March 14, 2025 — without any public accounting of what each cost.
What remains hidden is, in sum: the identity of every compounding pharmacy BOP has paid with public funds; the price per dose of pentobarbital in every federal execution since 2020; the total personnel cost of each execution; the capital improvement costs for the execution chamber at USP Terre Haute; and whether drug stockpiles were maintained during the 2021-2025 moratorium or whether new procurement was required in 2025, and at what cost. The instrument that would reveal most of this is straightforward: a mandatory appropriations rider requiring BOP to submit to the House and Senate Appropriations Committees, within 60 days of each execution, a per-execution cost report disaggregating drugs, personnel, facilities, transport, and legal services — with vendor identities submitted under classified annex to the relevant oversight committees if public disclosure is genuinely precluded on safety grounds. No such rider exists. None has been introduced.